NCT05026554招募中不适用
Pathophysiological Characterization of Chronic Hand Eczema Subtypes and Atopic Dermatitis With Noninvasive Molecular and Imaging Techniques in Subjects With Moderate to Severe Chronic Hand Eczema, Subjects With Atopic Dermatitis, and Healthy Volunteers
Dr. Robert Bissonnette1 个研究点 分布在 1 个国家目标入组 270 人开始时间: 2021年6月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 270
- 试验地点
- 1
- 主要终点
- Characterize differences in skin morphological parameters
研究概览
简要总结
Prospective longitudinal study to characterize Choronic Hand Eczema (CHE) subtypes and Atopic Dermatitis (AD) with noninvasive molecular and imaging techniques, and assess changes through time and its association with quality of life.
详细描述
Prospective longitudinal study of adult patients with moderate to severe chronic hand eczema, subject with modreate to severe Atopic Dermatitis and healthy volenteers to assess changes in morphological parameters and molecular signatures with non-invasive techniques.In addition, disease severity and their association with occupation, smoking status, quality of life will be evaluated per CHE subtypes and compared to subjects with only AD. Samples and data collected from healthy volunteers will be used as controls in the analyses.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects:
- •Male or female subjects aged 18 to 65 years, inclusive, at the time of consent.
- •Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
- •Subject must be willing to comply with all study procedures and must be available for the duration of the study.
- •CHE subjects only:
- •Subject has at least a 6-month history of CHE before Screening (information obtained from medical chart or subject's physician, or directly from the subject).
- •Subject has moderate to severe CHE as defined by an IGA score of ≥3 at Screening and Day
- •Subject has CHE covering ≥0.25% of BSA on palmar surface of hands at Screening and Day
- •Subjects has CHE that can be categorized in one of the following CHE subtypes at Day 1:
- •Atopic hand eczema (without wet-work or excessive contact with irritants)
- •Irritant contact hand eczema without atopic disease
- •Hyperkeratotic hand eczema without atopic disease
- •Vesicular hand dermatitis without atopic disease
- •Allergic contact hand eczema without atopic disease
- •Idiopathic hand eczema without wet-work, excessive contact with irritants, atopic disease, hyperkeratotic morphology, allergic contact hand eczema and vesicular hand eczema.
- •Subjects with only AD:
- •Subject has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and Rajka criteria.
- •Subject has at least a 6-month history of AD and had no significant flares in AD for at least 4 weeks before Screening (information obtained from medical chart or subject's physician, or directly from the subject).
- •Subject has moderate to severe AD as defined by a vIGA-AD score of ≥3 at Screening and Day
- •Subject has AD covering ≥0.5% of BSA at Screening and Day
- •Subject has an AD lesion covering ≥0.25% of BSA on the forearm at Screening and Day 1.Healthy Volunteers only:
- •Subject is in good general health, according to the investigator's judgment based on medical history and physical examination.
排除标准
- •All subjects:
- •Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
- •Subject has used systemic antibiotics within 2 weeks prior to Day
- •Subject has used topical antibiotics within 1 week prior to Day
- •Subject has used topical products containing urea or salicylic acid within 1 week prior to Day
- •Subject has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day
- •Subject is currently receiving a nonbiological investigational product or device or has received one within 4 weeks prior to Day
- •Subject has had excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths within 4 weeks prior to Day
- •Use of sunscreen products are recommended when exposure cannot be avoided.
- •Subject is a female who is pregnant or who is planning to become pregnant during the study.
- •CHE subjects only:
- •Subject has clinically infected chronic hand eczema on hands and/or wrists.
- •Subject with suspected or proven hand eczema protein contact dermatitis.
- •Subject has used doxepin within 1 week prior to Day
- •Subject has used hydroxyzine or diphenhydramine within 1 week prior to Day
- •Subject has used any topical medicated treatment that could affect CHE within 1 week prior to Day 1, including, but not limited to, topical corticosteroids, topical retinoids, crisaborole, calcineurin inhibitors, tars, antimicrobials, medical devices, and bleach baths.
- •Subject has used alitretinoin, isotretinoin, acitretin or other systemic retinoids within 4 weeks before Day 1, or has not completely recovered from its side effects.
- •Subject has used systemic treatments (other than biologics) that could have an impact on CHE less than 4 weeks prior to Day 1 (eg, calcineurin inhibitors, methotrexate, cyclosporin, hydroxycarbamide [hydroxyurea], azathioprine), or systemic steroids (including oral or injectable corticosteroids).
- •Note: Intranasal corticosteroids, eye or ear drops containing corticosteroids, and inhaled corticosteroids for stable medical conditions are allowed.
- •Subject has used dupilumab within 12 weeks prior to Day
- •Subject has received any UV-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day
- •Subject has had psoralen-UV-A (PUVA) treatment within 4 weeks prior to Day
- •Subjects with only AD:
- •Subject has clinically infected AD.
- •Subject has AD lesion on hand and/or feet at screening or Day
- •Subject has received an intravenous immunoglobulin (IVIg) therapy within 12 weeks prior to Day
- •Subject has used doxepin within 1 week prior to Day
- •Subject has used hydroxyzine or diphenhydramine within 1 week prior to Day
- •Subject has used any topical, medicated treatment that could affect AD within 1 week prior to Day 1, including, but not limited to, topical corticosteroids, crisaborole, calcineurin inhibitors, ruxolitinib, tars, antimicrobials, medical devices, and bleach baths.
- •Subject has used systemic treatments (other than biologics) that could affect AD less than 4 weeks prior to Day 1, including, but not limited to, retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxycarbamide (hydroxyurea), azathioprine, oral/injectable corticosteroids, baricitinib, upadacitinib, and abrocitinib.
- •Subject has used dupilumab within 12 weeks prior to Day
- •Subject has received any UV-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day
- •Subject has had PUVA treatment within 4 weeks prior to Day
- •Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are allowed.
- •Subject has used tralokinumab within 12 weeks prior to Day
- •Healthy Volunteers only:
- •Subject has history of atopic dermatitis, allergic rhinitis, or asthma.
结局指标
主要结局
Characterize differences in skin morphological parameters
时间窗: 12 months
Determine differences in skin morphological parameters between cohorts assessed with Hand Eczema Severity Index (HECSI). The HECSI scoring system incorporates both the extent and the intensity of the disease. Each hand will be divided into five areas (fingertips, fingers \[except the tips\], palms, back of hands and wrists). For each of these areas the intensity of the six following clinical signs: erythema, induration ⁄ papulation, vesicles, fissuring, scaling and oedema will be graded on the following scale: 0, no skin changes; 1, mild disease; 2, moderate and 3, severe. For each location (total of both hands) the affected area will be given a score from 0 to 4 (0, 0%; 1, 1-25%; 2, 26-50%; 3, 51-75% and 4, 76-100%) for the extent of clinical symptoms.
Characterize differences in skin molecular signature
时间窗: 12 months
Determine differences in skin molecular signatures between cohorts by comparing gene expression profiles from skin tissue collected with tape strips.
次要结局
- Determine disease severity impact on lifestyle(12 months)
- Determine disease severity impact on quality of life(12 months)
- To biobank plasma, serum, whole blood, DNA (buffy coat), stool, skin surface material and skin tissue.(10 years)
研究者
Dr. Robert Bissonnette
Principal Investigator
Innovaderm Research Inc.
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Chronic Hand Eczema - Self-management and PrognosisChronic Hand EczemaChronic Hand DermatitisNCT01482663University Hospital, Gentofte, Copenhagen306
已完成
3 期
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand EczemaChronic Hand EczemaNCT05259722LEO Pharma513
已完成
不适用
Painful Itch in Hand Eczemas: Frequency and Characteristicsin a Consecutive, Representative Collective ofDermatological PatientsL29.9Pruritus, unspecifiedDRKS00005238Klinik für Hautkrankheiten und Kompetenzzentrum chronischer Pruritus (KCP) Universitätsklinikum Münster1,471
已完成
4 期
Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone TriclosanChronic Hand EczemaNCT03246776Beijing Friendship Hospital80
已完成
不适用
Paraffin Bath Therapy for Chronic Hand EczemaEczemaNCT04510961Cairo University60